 Connection
James Cooper to Immunosuppressive Agents
This is a "connection" page, showing publications James Cooper has written about Immunosuppressive Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.573 |
|
|
|
-
Davis S, Gralla J, Klem P, Stites E, Wiseman A, Cooper JE. Tacrolimus Intrapatient Variability, Time in Therapeutic Range, and Risk of De Novo Donor-Specific Antibodies. Transplantation. 2020 04; 104(4):881-887.
Score: 0.521
-
Cooper JE. Evaluation and Treatment of Acute Rejection in Kidney Allografts. Clin J Am Soc Nephrol. 2020 03 06; 15(3):430-438.
Score: 0.516
-
Cooper JE, Gralla J, Klem P, Chan L, Wiseman AC. High dose intravenous immunoglobulin therapy for donor-specific antibodies in kidney transplant recipients with acute and chronic graft dysfunction. Transplantation. 2014 Jun 27; 97(12):1253-9.
Score: 0.349
-
Alfonso J, Gralla J, Klem P, Chan L, Wiseman AC, Cooper JE. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts. Clin Transpl. 2014; 161-70.
Score: 0.338
-
Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases. Clin Transpl. 2010; 415-20.
Score: 0.256
-
Davis S, Gralla J, Klem P, Tong S, Wedermyer G, Freed B, Wiseman A, Cooper JE. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. Am J Transplant. 2018 04; 18(4):907-915.
Score: 0.110
-
Mithani Z, Gralla J, Adebiyi O, Klem P, Cooper JE, Wiseman AC. De Novo Donor-Specific Antibody Formation in Tacrolimus-Based, Mycophenolate Versus Mammalian Target of Rapamycin Immunosuppressive Regimens. Exp Clin Transplant. 2018 02; 16(1):23-30.
Score: 0.105
-
Gralla J, Le CN, Cooper JE, Wiseman AC. The risk of acute rejection and the influence of induction agents in lower-risk African American kidney transplant recipients receiving modern immunosuppression. Clin Transplant. 2014 Mar; 28(3):292-8.
Score: 0.085
-
Renner B, Klawitter J, Goldberg R, McCullough JW, Ferreira VP, Cooper JE, Christians U, Thurman JM. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol. 2013 Nov; 24(11):1849-62.
Score: 0.083
-
Cooper JE, Gralla J, Chan L, Wiseman AC. Clinical significance of post kidney transplant de novo DSA in otherwise stable grafts. Clin Transpl. 2011; 359-64.
Score: 0.069
-
Cooper JE, Huskey J, Chan L, Wiseman AC. Preemptive retransplant for BK virus nephropathy without concurrent transplant nephrectomy. Transplantation. 2010 Aug 15; 90(3):331-2.
Score: 0.067
-
Cooper JE, Wiseman AC, Chan L. Bortezomib use in chronic antibody-mediated allograft dysfunction: a report of three cases. Clin Transpl. 2009; 455-9.
Score: 0.060
-
Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation. 2009 Oct 15; 88(7):891-6.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|